The PSMF is requested for every pharmacovigilance inspection. Where to keep it and when to provide it


The registration holder describes its pharmacovigilance system in a pharmacovigilance system master file (PSMF). The master file confirms the system’s compliance with the requirements of Union acts and member state legislation; the registration holder uses it to plan audits, and authorized bodies use it to plan and conduct inspections (under the Good Pharmacovigilance Practice Rules of the Eurasian Economic Union (EAEU), approved by Decision of the Council of the Eurasian Economic Commission (EEC) No. 87 of 3 November 2016, hereinafter Rules No. 87).
The PSMF is requested in preparation for every inspection: the request requires the current version of the file (under the Rules for Conducting Pharmaceutical Inspections for Compliance with the Requirements of the EAEU Good Pharmacovigilance Practice Rules, approved by Decision of the EEC Council No. 83 of 3 November 2016, hereinafter the Pharmacovigilance Inspection Rules).
In Russia, the registration holder’s fulfilment of its pharmacovigilance obligations is confirmed through an inspection at the registration holder’s own expense (under Resolution of the Government of the Russian Federation No. 353 of 12 March 2022, hereinafter Resolution No. 353). This provision applies up to and including 31 December 2029. It was introduced into Resolution No. 353, together with the rest of the inspection procedure, by Resolution of the Government of the Russian Federation No. 1028 of 19 August 2026.
A scheduled inspection is conducted within 3 years after a medicinal product is released into civil circulation, if the product has been manufactured in Russia for the first time or imported into Russia for the first time. The registration holder applies for the inspection within 3 months after that release.

What the EAEU rules require of the master file

The PSMF describes the pharmacovigilance system for one or more of the registration holder’s medicinal products and provides authorities with an overview of the system during and after registration. Preparing and updating the PSMF helps the registration holder and the Qualified Person for Pharmacovigilance (QPPV) check whether the system has been implemented in accordance with the requirements and identify its deficiencies and risks.
The QPPV is responsible for establishing and operating the pharmacovigilance system and has authority and responsibility in relation to the PSMF. The registration holder grants the QPPV access to the PSMF and ensures that they receive information about any changes to it. The QPPV must have continuous access to the PSMF. One QPPV is permitted per system. Several registration holders may use the services of the same QPPV, and the QPPV may work under a contract without being an employee of the registration holder. In addition to the QPPV, authorized bodies may require the appointment of a pharmacovigilance contact person accountable to the QPPV.
The registration holder submits a PSMF with its first application for registration of a medicinal product on the Union market. Subsequent applications are accompanied by a summary of the pharmacovigilance system (under the Rules for Registration and Regulatory Review of Medicines for Medical Use, approved by Decision of the EEC Council No. 78 of 3 November 2016, hereinafter Rules No. 78). Under Rules No. 87, the summary includes written confirmation that a QPPV is in place, the country where the QPPV resides and works, contact details for the QPPV and the contact person, if any, a declaration signed by the registration holder concerning fulfilment of its obligations, and the address where the PSMF is kept. If the registration holder is not located in a member state, Rules No. 78 additionally require confirmation that a pharmacovigilance contact person is in place in a member state.
The Federal Service for Surveillance in Healthcare (Roszdravnadzor) may obtain the PSMF without approaching the registration holder itself. Under Federal Law No. 61-FZ of 12 April 2010 «On the Circulation of Medicines» (hereinafter 61-FZ), the federal authority responsible for state registration of medicinal products provides information on medicines to Roszdravnadzor upon its request. This provision was introduced by Federal Law No. 1-FZ of 30 January 2024. The list of such information includes the PSMF and the risk management plan, and these are provided even where they constitute trade secrets.

What the PSMF contains

The PSMF must have a table of contents. Its sections contain the core information, while detailed information that changes frequently may be placed in annexes. There are eight core sections, set out in Table 1.

Table 1. Core sections of the PSMF

PSMF sectionWhat it describes
Qualified Person for PharmacovigilanceDuties and powers, qualifications and experience, contact details, cover during absence, and the contact person’s scope of responsibility, if applicable
Organizational structure of the registration holderThe organization’s structure and the QPPV’s position within it; the addresses where reports are collected and assessed, the database is managed, and work on reports, signals and risk management plans is performed
Delegated tasksContracts and agreements with contractors and partners, presented as a list or table
Sources of safety dataDepartments receiving reports, studies, registries and programs, including those completed within the past 2 years
Computerized systems and databasesLocation, functions, responsibilities, validation status, change control, backup procedures and archiving
ProcessesStandard operating procedures (SOPs), data types, record-keeping, benefit-risk assessment, signals, reports and amendments to the instructions for use
System performanceIndicators of reporting timeliness and quality, and analysis of the fulfilment of risk management plan obligations
Quality systemDocument and record control, staff training, audits and deviations

The annexes are designated by the letters А to И (Table 2).

Table 2. Annexes to the PSMF

AnnexContents
АQPPV information: a list of tasks delegated to the QPPV, a curriculum vitae with supporting documents, and additional contact details
БOrganizational structure of the registration holder: lists of contracts and agreements
ВSources of safety data: the registration holder’s branches and third-party contact details
ГComputerized systems and databases
ДWritten processes and procedures: a list of procedural documents
ЕSystem effectiveness: indicators and current assessment results
ЖQuality system: the audit plan and a list of audits conducted and completed
ЗMedicinal products covered by the system: a list of products and comments concerning the registration holders
ИRecord and document control: the change log and documentation of the annexes’ change history

If an annex is absent, pages with no content need not be provided. The remaining annexes retain their letters: if Annex Г is not used, Annex Д still remains Annex Д. Such an annex is identified in the table of contents as «not used».
The PSMF may be maintained electronically, provided that a clearly structured printed copy can be supplied at the request of the authorized body. In any format, the PSMF must be legible, complete and accessible, allow all documents to be assessed and enable changes to be traced. Electronic tagging of the document and searchable text are recommended. The title page states the PSMF number, if available, the registration holder’s name, the QPPV, the names of other registration holders using the same system, the list of the registration holder’s PSMFs for products covered by another pharmacovigilance system, and the date of preparation or last update.
Documents referenced in the PSMF must be available for submission. Copies of individual agreements with contractors are provided at the request of authorized bodies or during an inspection or audit. The full referenced report and documents containing the corrective and preventive action plan are attached to the audit list. Documents concerning specific local procedures not included in the general list are provided at the request of the authorized body, identifying the countries where they apply.

Where to keep the PSMF, how to amend it and when to make it available

The PSMF is kept in a member state, either at the location where the registration holder actually carries out its principal pharmacovigilance activities or at the address of the QPPV’s principal place of work, regardless of the document’s format. The summary information provided to authorized bodies must not specify more than one location for the same PSMF.
The registration holder registers the PSMF location with the authorized body when submitting an application for registration of a medicinal product. The authority of the member state must be informed of any change in that location without delay and no later than 30 calendar days. If the QPPV or their contact details change, or if the PSMF location changes, the registration holder submits a variation application to the authorized bodies. Work on the PSMF may be assigned to a third party, but responsibility for compliance with the requirements remains with the registration holder.
The PSMF describes the system currently in operation. Components still being implemented are identified as planned. The information in the PSMF must be exhaustive and correct as of the current date.
The registration holder provides authorized bodies with access to the PSMF within 7 working days after receiving a request. Authorized bodies are also given direct access to the PSMF at the location where it is kept or at the QPPV’s place of work. The registration holder provides a legible copy of the PSMF, electronically or on paper, within the same 7 working days. Other PSMF-related time limits are set out in Table 3.

Table 3. PSMF-related time limits

RequirementTime limit
Inform the authority of the member state of a change in the PSMF locationWithout delay and no later than 30 calendar days
Provide authorized bodies with access to the PSMF and a copy upon request7 working days from receipt of the request
Maintain the PSMF change logCovering the past 5 years
Provide a list of auditsAudits completed within the past 5 years and planned audits; if the system has existed for less than 5 years, covering its actual period of operation
Provide a list of studies and programsOngoing studies and programs and those completed within the past 2 years
Retain PSMF documentsFor as long as the system described remains in operation and for at least 5 years after its termination

Types of inspection and when to apply

Inspections of pharmacovigilance practice are organized by Roszdravnadzor and conducted by a federal state budgetary institution subordinate to it. Roszdravnadzor designates that institution in accordance with a procedure established by the Russian Ministry of Health and publishes its name on its website. Inspections are conducted in accordance with the procedure established by Rules No. 87 and EEC Council Decision No. 83 of 3 November 2016, «On Approval of the Rules for Conducting Pharmaceutical Inspections», at the registration holder’s expense. The Russian Ministry of Health determines the methodology for calculating the fee.
Roszdravnadzor transfers data on medicinal products being released into civil circulation from its automated information system to the subordinate institution; on the day it issues a requirement for an unscheduled inspection, it also sends the institution information about that requirement. Inspections may be scheduled, repeat or unscheduled. The time limits for each type and the deadlines for the registration holder’s applications are set out in Table 4.

Table 4. Types of inspection and deadlines for registration holder applications

Type of inspectionWhen it is conductedWhen the registration holder applies
Scheduled inspectionWithin 3 years after a medicinal product is released into civil circulation, for registration holders of products manufactured in Russia for the first time or imported into Russia for the first time, irrespective of strength and within a single registration certificateWithin 3 months after the product is released into civil circulation
Repeat inspectionWithin 3 years after completion of the scheduled inspection, if it identified the registration holder’s non-compliance with pharmacovigilance practiceWithin 3 months after receipt of the inspection report containing information on non-compliance
Unscheduled inspectionWithin 3 months after Roszdravnadzor sends a requirement, if the periodic safety update reports (PSURs) submitted for the calendar year contain no benefit-risk assessment based on up-to-date data, including an analysis of adverse reactions from Roszdravnadzor’s information system; or within 3 months after the registration holder submits an application, if the previous inspection report contains information on critical deficienciesWithin 30 calendar days after receipt of the requirement or inspection report referred to in the preceding column

If the registration holder fails to submit one of these applications, the subordinate institution notifies it that an application is required. The application is then submitted no later than one month after receipt of the notification. The time limit for applying for an unscheduled inspection is suspended for the duration of an appeal against the findings, if the registration holder has lodged an appeal. An inspection may also be conducted upon an application submitted by the registration holder on its own initiative.

When Roszdravnadzor considers an unscheduled inspection under Order No. 3518

Order of Roszdravnadzor No. 3518 of 17 June 2024 «On Approval of the Procedure for Pharmacovigilance of Medicinal Products for Medical Use» (hereinafter the Pharmacovigilance Procedure), is in effect from 1 March 2025 until 1 March 2031 and replaced Orders No. 1071 of 15 February 2017 and No. 6252 of 16 July 2020, which have been repealed. The registration holder’s pharmacovigilance system must comply with Rules No. 87.
The Pharmacovigilance Procedure specifies circumstances in which Roszdravnadzor considers an unscheduled inspection of the registration holder’s pharmacovigilance system:
the expert organization has identified non-compliance in the PSUR or development safety update report for a single medicinal product on three consecutive occasions, and Roszdravnadzor has received information about this from that organization;
the expert organization has identified a failure to comply with mandatory pharmacovigilance requirements, in which case Roszdravnadzor also considers suspending use of the product;
the expert organization has identified non-compliance in the registration holder’s materials concerning additional risk minimization measures on three consecutive occasions, in which case Roszdravnadzor also considers suspending use of the product.

The inspection procedure and handling the report

On the basis of applications submitted in the previous year and by 31 March of the current year, the subordinate institution sends Roszdravnadzor proposals by 15 April of the current year to include registration holders in the inspection list for the current and following year. For an application for an unscheduled inspection, proposals for the date are sent within 2 working days. Roszdravnadzor publishes the inspection list on its website.
For a scheduled inspection, notification is sent at least 45 calendar days before the planned date. For an unscheduled inspection, the notification period may be shortened depending on the triggering factor and the risk. In exceptional circumstances, an inspection is conducted without prior notification if an important risk to public health or to the operation of the pharmacovigilance system requires urgent assessment. The notification specifies the version number of the current PSMF and the type of inspection.
A request for information needed to prepare for the inspection is sent to the QPPV at least 30 calendar days before the planned date. The request itself specifies the deadline and method for submitting the documents.
In the inspection report form, the PSMF is assessed in a separate row against three aspects: format, content, and maintenance and availability. Each deficiency is assigned to one of three categories: critical, major or minor.
The inspection report is prepared within 30 working days after completion of the inspection. The registration holder receives it before preparation is finalized so that it can comment. Within 30 working days after receiving the report, the registration holder submits a corrective and preventive action plan. The final version of the report is prepared within 10 working days after receipt of the registration holder’s response.
If the registration holder disagrees with the findings, it lodges an appeal with Roszdravnadzor within 5 working days after receiving the inspection report. This applies to reports containing information on deficiencies. Roszdravnadzor considers the appeal within no more than 30 calendar days. It either upholds the appeal in full or in part and requires the subordinate institution to amend the report, if the requirements of pharmacovigilance practice or the Pharmacovigilance Inspection Rules have been breached or the report’s conclusions are inaccurate, or dismisses the appeal. The subordinate institution sends the amended report to the registration holder and Roszdravnadzor within 5 working days.
According to a report published by Pharmvestnik on 25 September 2026, a Roszdravnadzor representative speaking at an event in Kaliningrad on 24 and 25 September 2026 indicated a target of approximately 120 pharmacovigilance inspections per year. According to the same report, the checklists were not ready, and the fee calculation methodology was under review by the legal department of the Russian Ministry of Health. These details are not contained in the legal provision; they are taken from a news report.

Consequences of non-compliance

Within 5 working days after the application deadline expires or the inspection report is sent to the registration holder, the subordinate institution informs Roszdravnadzor in three circumstances:
the registration holder has failed to submit an application within the prescribed period;
the registration holder has failed to enable the inspection to be conducted or has not paid its costs;
the registration holder has failed to remedy the deficiencies specified in the Pharmacovigilance Inspection Rules.

Roszdravnadzor forwards this information to the Russian Ministry of Health within 5 working days after receiving it, so that a decision provided for in Rules No. 78 can be taken.
Under Rules No. 78, the authorized body suspends the registration certificate or restricts use of the medicinal product in several circumstances, including where the registration holder fails to fulfil its pharmacovigilance obligations. Under Rules No. 78, the registration certificate is revoked (cancelled) if the registration holder fails to comply with the requirements of the authorized body imposed on those grounds.

What to do

Determine how many pharmacovigilance systems you have and which PSMF describes each one. Each system is described in a separate PSMF. Together, all PSMFs cover all of the registration holder’s medicinal products.
Draw up a list of systems: the general system, a separate system for vaccines, and a system shared with a licensing partner.
Check Annex З to the PSMF against the register of registration certificates: trade names, international non-proprietary names, certificate numbers and countries must match.
For shared systems, provide cross-references to partners’ PSMFs and contractual rights of access to them.
Check the PSMF location and the QPPV’s details against the information declared to regulators.
Check that a single address is specified for each PSMF and that the choice of location is justified.
If the address or the QPPV’s contact details have changed, submit a variation application and check that the 30-calendar-day deadline for reporting a change in the PSMF location has not expired.
Compare the contact details in Annex А to the PSMF with those in the registration documents.
Check that each section is supported by documentation. Describe the system currently in operation, and mark components still being implemented as planned.
In the processes section, provide references to current SOPs, specifying their number, title, effective date and type.
In the computerized systems section, specify the validation status, change control, backup procedures and archiving.
Check the system performance section against the PSURs for the calendar year: Roszdravnadzor issues a requirement for an unscheduled inspection if the PSURs contain no benefit-risk assessment based on up-to-date data.
Establish change control and a change log. The change log covering the past 5 years records the date of each change, the person responsible and a description of the change.
Establish arrangements to ensure that the QPPV learns of changes immediately, and obtain their written confirmation of acceptance of the duties relating to maintenance of the PSMF.
Introduce a system for managing changes to the PSMF and processes for receiving information about changes in a timely manner.
Maintain a list of audits covering 5 years, together with comments on audits with significant findings until the corrective actions have been fully implemented.
Prepare arrangements for providing the PSMF and a calendar of deadlines. Check how you would provide the PSMF if a request arrived today.
Make sure that a legible copy of the PSMF can be provided within 7 working days, electronically or on paper, and that authorized bodies can obtain direct access at the location where the PSMF is kept.
Enter in the calendar the deadline for applying for a scheduled inspection (3 months after the product is released into civil circulation), the application deadline following a requirement for an unscheduled inspection (30 calendar days), and the deadline for appealing against the report (5 working days).
Allow for the deadline for the corrective and preventive action plan (30 working days after receipt of the inspection report).


Regulatory framework:

1. Decision of the Council of the Eurasian Economic Commission No. 87 of 3 November 2016 «On Approval of the Good Pharmacovigilance Practice Rules of the Eurasian Economic Union» (as amended on 19 May 2022)
2. Decision of the Council of the Eurasian Economic Commission No. 78 of 3 November 2016 «On the Rules for Registration and Regulatory Review of Medicines for Medical Use» (as amended on 26 November 2025)
3. Decision of the Council of the Eurasian Economic Commission No. 83 of 3 November 2016 «On Approval of the Rules for Conducting Pharmaceutical Inspections» (as amended on 1 August 2025), including the Rules for Conducting Pharmaceutical Inspections for Compliance with the Requirements of the Good Pharmacovigilance Practice Rules of the Eurasian Economic Union
4. Federal Law No. 61-FZ of 12 April 2010 «On the Circulation of Medicines» (as amended on 4 August 2026)
5. Federal Law No. 1-FZ of 30 January 2024 «On Amendments to the Federal Law ‘On the Circulation of Medicines’ and Articles 1 and 4 of the Federal Law ‘On Amendments to the Federal Law «On the Circulation of Medicines»‘»
6. Resolution of the Government of the Russian Federation No. 353 of 12 March 2022 «On Special Provisions for Permitting Activities in the Russian Federation» (as amended on 23 September 2026)
7. Resolution of the Government of the Russian Federation No. 1028 of 19 August 2026 «On Amendments to Annex No. 28 to Resolution No. 353 of the Government of the Russian Federation of 12 March 2022»
8. Order of the Federal Service for Surveillance in Healthcare No. 3518 of 17 June 2024 «On Approval of the Procedure for Pharmacovigilance of Medicinal Products for Medical Use»
9. Order of the Federal Service for Surveillance in Healthcare No. 1071 of 15 February 2017 «On Approval of the Procedure for Carrying Out Pharmacovigilance»; repealed
10. Order of the Federal Service for Surveillance in Healthcare No. 6252 of 16 July 2020 «On Amendments to the Procedure for Carrying Out Pharmacovigilance Approved by Order No. 1071 of the Federal Service for Surveillance in Healthcare of 15 February 2017»; repealed
11. Pharmvestnik. «Roszdravnadzor Plans to Conduct Approximately 120 Pharmacovigilance Inspections per Year.» 25 September 2026 (author: Ekaterina Pogontseva)

This page in Russian→